Overexpression of long non‑coding RNA cancer susceptibility�11 is involved in the development of chemoresistance to carboplatin in hepatocellular carcinoma
Haidong Liu, Tao Liu, Yong Zhou, Xinwen Song, Rendong Wei
Abstract
Open-access reader
Haidong Liu, Tao Liu, Yong Zhou, Xinwen Song, Rendong Wei
Abstract
Open-access reader
The long non‑coding (lnc)RNA cancer susceptibility 11 (CASC11) promotes gastric cancer, however its role in other diseases is unknown. The present study demonstrated upregulation of lncRNA CASC11 and microRNA (miR)‑21 in hepatocellular carcinoma (HCC). Furthermore, the expression of CASC11 was positively correlated with that of miR‑21 in HCC tumors. Moreover, overexpression of lncRNA CASC11 led to upregulation of miR‑21 in HCC cells, whereas overexpression of miR‑21 had no effect on CASC11 levels. The levels of lncRNA CASC11 and miR‑21 were found to be upregulated in the plasma of patients with HCC during chemotherapy. In vitro cell experiments demonstrated upregulation of lncRNA CASC11 in HCC cells treated with carboplatin. Additionally, overexpression of lncRNA CASC11 promoted, whereas its knockdown inhibited the viability of HCC cells following carboplatin treatment. Finally, overexpression of miR‑21 ameliorated the effects of lncRNA CASC11 knockdown on cell viability. Thus, these findings suggest that upregulation of lncRNA CASC11 is involved in the development of chemoresistance to carboplatin in patients with HCC, via the upregulation of miR‑21.
OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The long non‑coding (lnc)RNA cancer susceptibility 11 (CASC11) promotes gastric cancer, however its role in other diseases is unknown. The present study demonstrated upregulation of lncRNA CASC11 and microRNA (miR)‑21 in hepatocellular carcinoma (HCC). Furthermore, the expression of CASC11 was positively correlated with that of miR‑21 in HCC tumors. Moreover, overexpression of lncRNA CASC11 led to upregulation of miR‑21 in HCC cells, whereas overexpression of miR‑21 had no effect on CASC11 levels. The levels of lncRNA CASC11 and miR‑21 were found to be upregulated in the plasma of patients with HCC during chemotherapy. In vitro cell experiments demonstrated upregulation of lncRNA CASC11 in HCC cells treated with carboplatin. Additionally, overexpression of lncRNA CASC11 promoted, whereas its knockdown inhibited the viability of HCC cells following carboplatin treatment. Finally, overexpression of miR‑21 ameliorated the effects of lncRNA CASC11 knockdown on cell viability. Thus, these findings suggest that upregulation of lncRNA CASC11 is involved in the development of chemoresistance to carboplatin in patients with HCC, via the upregulation of miR‑21.
Key concepts: Downregulation and upregulation, Gene knockdown, Carboplatin, Long non-coding RNA, Oncogene, Cancer research, Hepatocellular carcinoma, microRNA